New hope for hodgkin lymphoma: maintenance drug after transplant

NCT ID NCT06812858

Recruiting now Disease control Sponsor: St. Petersburg State Pavlov Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a drug called a PD-1 inhibitor can help keep Hodgkin lymphoma from coming back after a stem cell transplant. It is for people whose lymphoma returned or did not respond to earlier treatments. About 83 adults will receive the drug as maintenance therapy and be followed for up to 2 years to see if it improves cancer control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

classic Hodgkin lymphoma Hodgkins lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HODGKIN LYMPHOMA

Contacts and locations

Locations

National Medical and Surgical Center named after N.I. Pirogov
RECRUITING

Moscow, Russia
National Research Oncology Center
RECRUITING

Astana, Kazakhstan
RM Gorbacheva Research Institute, Pavlov University
RECRUITING

Saint Petersburg, Russia
RecruitingP. Hertsen Moscow Oncology Research Institute (MORI) for administrative and economic work - the branch of the FSBI "National Medical Research Radiological Centre" (NMRRC) of the Ministry of Health of the Russian Federation
RECRUITING

Moscow, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.